At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MCI Babson Capital Corporate Investors
Not Yet Opened 03-05 16:00:00 EST
20.42
+0.04
+0.20%
盘后20.42
+0.000.00%
16:10 EST
High20.56Low20.27Vol7.88K
Open20.46D1 Closing20.38Amplitude1.40%
Mkt Cap418.58MTradable Cap0.00Total Shares20.50M
T/O160.85KT/O Rate--Tradable Shares0.00
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Barings Corporate Investors Publishes 2025 Annual Report
Reuters  ·  03-01
Barings Corporate Investors Publishes 2025 Annual Report
Barings Corporate Investors Q4 net unrealized appreciation at USD 986,805.0 million after Q3 net unrealized depreciation of USD 419,454.0 million
Reuters  ·  02-27
Barings Corporate Investors Q4 net unrealized appreciation at USD 986,805.0 million after Q3 net unrealized depreciation of USD 419,454.0 million
Barings Corporate Investors Q4 Dividend USD 0.4
THOMSON REUTERS  ·  02-27
Barings Corporate Investors Q4 Dividend USD 0.4
Press Release: Barings Corporate Investors Reports Preliminary Fourth Quarter 2025 Results
Dow Jones  ·  02-27
Press Release: Barings Corporate Investors Reports Preliminary Fourth Quarter 2025 Results
Barings Corporate Investors announces $0.40 per share quarterly dividend
Reuters  ·  2025-12-12
Barings Corporate Investors announces $0.40 per share quarterly dividend
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
GlobeNewswire  ·  2025-12-04
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
GlobeNewswire  ·  2025-12-03
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
GlobeNewswire  ·  2025-11-28
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
GlobeNewswire  ·  2025-11-25
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
GlobeNewswire  ·  2025-11-14
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
Barings Corporate Investors reports Q3 net investment income of $7.1 million
Reuters  ·  2025-11-14
Barings Corporate Investors reports Q3 net investment income of $7.1 million
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
GlobeNewswire  ·  2025-11-05
Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
India Inflation Cools Further in September
MT Newswires Live  ·  2025-10-14
India Inflation Cools Further in September
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
GlobeNewswire  ·  2025-10-14
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
GlobeNewswire  ·  2025-09-24
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
How a new three-minute memory test can help spot Alzheimer's disease
Switzer  ·  2025-09-18
How a new three-minute memory test can help spot Alzheimer's disease
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target
GlobeNewswire  ·  2025-09-03
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
GlobeNewswire  ·  2025-09-03
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

Introduction

Company Name.
Babson Capital Corporate Investors
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Babson Capital Corporate Investors trust is a closed ended fixed income mutual fund launched and managed by Barings LLC. It invests in fixed income markets of the United States. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in a portfolio of privately placed, below-investment grade, long term corporate debt obligations. The fund also invests in marketable investment grade debt securities, other marketable debt securities, and marketable common stocks. It was formerly known as Babson Capital Corporate Investors. Babson Capital Corporate Investors trust was formed in 1971 and is domiciled in the United States.
Issue price:
--